-$0.40 EPS Expected for PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) This Quarter

Wall Street analysts predict that PhaseBio Pharmaceuticals Inc (NASDAQ:PHAS) will announce earnings per share of ($0.40) for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for PhaseBio Pharmaceuticals’ earnings. The highest EPS estimate is ($0.30) and the lowest is ($0.46). PhaseBio Pharmaceuticals posted earnings per share of ($0.26) in the same quarter last year, which indicates a negative year over year growth rate of 53.8%. The firm is expected to report its next earnings results on Tuesday, March 24th.

On average, analysts expect that PhaseBio Pharmaceuticals will report full year earnings of ($1.39) per share for the current financial year, with EPS estimates ranging from ($1.50) to ($1.21). For the next fiscal year, analysts expect that the firm will post earnings of ($1.79) per share, with EPS estimates ranging from ($2.15) to ($1.57). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow PhaseBio Pharmaceuticals.

PhaseBio Pharmaceuticals (NASDAQ:PHAS) last posted its quarterly earnings results on Thursday, November 14th. The company reported ($0.40) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.04). The company had revenue of $0.24 million during the quarter, compared to the consensus estimate of $0.35 million. PhaseBio Pharmaceuticals had a negative return on equity of 53.00% and a negative net margin of 1,768.29%.

A number of research firms recently commented on PHAS. ValuEngine cut shares of PhaseBio Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Cowen reiterated a “buy” rating on shares of PhaseBio Pharmaceuticals in a research note on Tuesday, September 24th. HC Wainwright began coverage on shares of PhaseBio Pharmaceuticals in a research note on Thursday, October 3rd. They issued a “buy” rating and a $18.00 price objective for the company. Stifel Nicolaus reduced their price objective on shares of PhaseBio Pharmaceuticals from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Monday, September 9th. Finally, William Blair reiterated an “outperform” rating on shares of PhaseBio Pharmaceuticals in a research note on Wednesday, September 11th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $17.56.

A number of institutional investors have recently added to or reduced their stakes in the stock. Strs Ohio purchased a new position in shares of PhaseBio Pharmaceuticals during the 2nd quarter valued at $48,000. JPMorgan Chase & Co. purchased a new position in PhaseBio Pharmaceuticals in the second quarter worth $48,000. TD Asset Management Inc. grew its position in PhaseBio Pharmaceuticals by 26.9% in the second quarter. TD Asset Management Inc. now owns 40,343 shares of the company’s stock worth $529,000 after acquiring an additional 8,555 shares in the last quarter. United Services Automobile Association grew its position in PhaseBio Pharmaceuticals by 15.8% in the second quarter. United Services Automobile Association now owns 107,267 shares of the company’s stock worth $1,407,000 after acquiring an additional 14,653 shares in the last quarter. Finally, Wells Fargo & Company MN purchased a new position in PhaseBio Pharmaceuticals in the second quarter worth $211,000. Institutional investors and hedge funds own 66.33% of the company’s stock.

NASDAQ:PHAS opened at $3.39 on Friday. The company has a current ratio of 13.98, a quick ratio of 16.52 and a debt-to-equity ratio of 0.13. The stock has a market capitalization of $96.37 million and a PE ratio of -0.76. The firm’s 50 day moving average is $4.00 and its 200 day moving average is $8.08. PhaseBio Pharmaceuticals has a 12 month low of $2.56 and a 12 month high of $16.65.

About PhaseBio Pharmaceuticals

PhaseBio Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat orphan diseases with an initial focus on cardiopulmonary indications. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor that has completed a Phase 1 clinical trial and is been developed for the treatment of patients on ticagrelor who are experiencing a major bleeding event or those who require urgent surgery.

Read More: What is the definition of arbitrage?

Get a free copy of the Zacks research report on PhaseBio Pharmaceuticals (PHAS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for PhaseBio Pharmaceuticals (NASDAQ:PHAS)

Receive News & Ratings for PhaseBio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PhaseBio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.